25 LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

25 LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-53	Closed	-$18.5K	–	558
2023 Q2	$18.5K	Sell	53 -1	-2%	-$337	0.01%	121
2023 Q1	$18.6K	Buy	+54	New	+$16.2K	0.01%	119

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

25 LLC's VRTX Position: Q3 2023 in Review

25 LLC sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 53 shares — an estimated $18.5K sold.

25 LLC first reported a position in VRTX in Q1 2023 and held it in 2 quarters. The position peaked at $18.6K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

25 LLC reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
25 LLC sold 53 Vertex Pharmaceuticals shares in Q3 2023, an estimated $18.5K.
25 LLC first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 2 quarters.
25 LLC's Vertex Pharmaceuticals position peaked at $18.6K in Q1 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.